XL-protein
Pre-clinicalXL-protein develops long-acting therapeutic proteins using its proprietary PASylation technology to extend half-life and improve drug properties.
Founded
2008
Focus
Drug Delivery
About
XL-protein develops long-acting therapeutic proteins using its proprietary PASylation technology to extend half-life and improve drug properties.
Funding History
3Total raised: $30M
Series B$20MBayern KapitalJun 15, 2018
Series A$10MHigh-Tech GründerfondsJun 15, 2015
GrantUndisclosedGerman Federal Ministry of Education and ResearchJun 15, 2012
Company Info
TypePrivate
Founded2008
LocationFreising, Germany
StagePre-clinical
Contact
SIMILAR COMPANIES
300Microns
Pre-clinical · Munich
BetaSense
Pre-clinical · Berlin
AB Diagnostic Systems
Pre-clinical · Jena
bbi-biotech
Pre-clinical · Berlin
Mireca Medicines
Pre-clinical · Munich
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile